IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval.

A study published in the journal Clinical & Experimental Allergy found that treatment with the drug dupilumab significantly reduces IgE production in patients with atopic dermatitis (AD) over a median of 2.5 years. The study also showed that IgE levels continue to decrease over time, regardless of the treatment interval. The researchers compared patients who extended the dosing interval of dupilumab to those who did not, as well as healthy volunteers. The findings suggest that dupilumab can effectively reduce IgE levels in AD patients, supporting the decision to extend the dosing interval in well-controlled cases. [Extracted from the article]